Skip to main content

BB Biotech Reports an MGNX Buy

October 26, 2022

The largest insider transaction on today’s list was reported in a Form 4 filing by the Swiss investment company BB Biotech AG.

The biotechnology-focused fund reported a purchase worth roughly $2.2 million in MacroGenics $MGNX.

In other Form 4 filings, both the Chief Risk Officer and a director of Texas Capital Bancshares $TCBI disclosed purchases of their own company's stock.

Here’s The Hot List, with data through October 25, 2022:

In another Form 4, director Kevin Stephens reported a purchase of 2,000 shares, equivalent to $247,000 of Crown Castle International $CCI stock.

In the options market, there was bullish flow in Microchip Technology $MCHP, Barrick Gold Corporation $GOLD, and Bed Bath & Beyond $BBBY.

Stay tuned. We'll be back Thursday with more insider action.

If you want these insider transactions e-mailed to you every morning, click here to sign up for The Hot Corner.

And please reach out with any questions. We love hearing from you!

All Star Charts Team